SecBot SecBot

ACAD

ACADIA PHARMACEUTICALS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001070494 Biotech & Drug Discovery
$18.67 −0.08 (−0.43%)
Nov 16 4:00 PM ET · prev $18.75
Market cap
$3.1B
Mid cap
Consensus
Buy
74% Buy or better · 27 analysts
Median target
$33.00
+77% · range $16.00–38.00
1 year
−22.2%
from $24.01 · Nov 17
30 days
−5.7%
from $19.80
52-week range
$16.50–30.57
−39% from high · low Nov 9
Avg volume 20D
2.75M
Nov 9 spike 12.15M
Short interest
8.32M
≈4.8% of shares · −8.5%
Days to cover
5.9
at average volume
Insider net
−$2.2M
0 buyers · 5 sellers · since Mar 25
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
14
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 5/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $2.2M.

  • InstitutionsMIXED

    Q2 2026: 31 added (0 new), 24 trimmed or exited.

  • AnalystsBULLISH

    20 of 27 rate it Buy or better. Median target $33.00 (+77%).

  • Short sellersSTEADY

    Short interest −8.5% to 8.32M shares. 5.9 days to cover, ≈4.8% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
GOLDMAN SACHS GROUP INCADD2,580,115$65.3M
Qube Research & Technologies LtdDOUBLED2,446,610$61.9M
CITADEL ADVISORS LLCDOUBLED2,182,177$55.2M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD1,969,445$49.8M
MARSHALL WACE, LLPDOUBLED1,764,838$44.7M
D. E. Shaw & Co., Inc.DOUBLED1,697,937$43.0M
Nuveen, LLCADD1,348,192$34.1M
RENAISSANCE TECHNOLOGIES LLCTRIM1,282,596$32.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

27 analysts
Buy 74% rate it Buy or better
Strong Buy8Buy12Hold6Sell1Strong Sell0
12-month targets · 19 analysts

Price is inside the target range. Median implies +77%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Nov 6, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Nov 5, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 19, 2026Needham
REITERATE
REITERATEBuy
Oct 13, 2026UBS
DOWNGRADE
DOWNGRADENeutral
Oct 8, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$2.2M
sold · 5 insiders
DateInsiderTypeValue
Oct 30, 2026
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Oct 30, 2026
SELL$69.3K
Oct 15, 2026
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Oct 15, 2026
AWARD6,815 sh
Aug 6, 2026
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 6, 2026
EXERCISE$255.0K
Aug 6, 2026
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 6, 2026
SELL$145.0K
Aug 6, 2026
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 6, 2026
SELL$272.6K
Aug 5, 2026
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 5, 2026
EXERCISE$104.3K
Aug 5, 2026
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Aug 5, 2026
SELL$169.6K
Jul 30, 2026
Thompson Elizabeth H.Z.
EVP, Head of Research & Dev
Jul 30, 2026
SELL$431.4K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

35 lobbying filings and 11 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
8,317,392
shares short
-8.5%
vs prior settlement
5.9
days to cover
≈4.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
State Street Corporation filed a Schedule 13G disclosing a 4.4% passive stake in Acadia Pharmaceuticals as of…
SC 13G · Impact 3/10
Nov 4, 2026 SEC
Acadia Pharmaceuticals reported Q3 2026 GAAP total revenues of $342M, up 22% YoY on a non-GAAP adjusted basis, and…
8-K · Impact 6/10
Nov 4, 2026 Earnings result
ACAD Q3 2026 Earnings: EPS $0.31 (+54.8% vs est)
Nov 3, 2026 SEC
Five asset managers increased their ACAD positions in Q3 2026, with two funds more than doubling their stakes. The…
INST-CLUSTER · Impact 3/10
Oct 30, 2026 Insider
Schneyer Mark C. sold 3,321 shares
EVP, CHIEF FINANCIAL OFFICER @ $20.88 ($69.3K)
Oct 15, 2026 Insider
Schneyer Mark C. was granted 6,815 shares
EVP, CHIEF FINANCIAL OFFICER
Aug 6, 2026 Insider
Schneyer Mark C. acquired via exercise 14,292 shares
EVP, CHIEF FINANCIAL OFFICER @ $17.84 ($255.0K)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC · ADD
2,580,115 shares ($65.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

14 filings · 3 bullish · 2 bearish · 1 mixed · 8 neutral
All ACAD filing & press-release reports (14)